Review of brachytherapy clinical trials: a cross-sectional analysis of ClinicalTrials.gov.
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
13 Feb 2024
13 Feb 2024
Historique:
received:
30
12
2023
accepted:
31
01
2024
medline:
14
2
2024
pubmed:
14
2
2024
entrez:
13
2
2024
Statut:
epublish
Résumé
Characterizing the landscape of clinical trials including brachytherapy can provide an overview of the current status and research trends which may guide further areas of investigation. We queried 449,849 clinical trials from the ClinicalTrials.gov registry using brachytherapy-related keywords from 1980 to 2023, yielding 245 multi-arm and 201 single-arm, brachytherapy trials. Multi-arm and single-arm brachytherapy trials were compared using 12 trial protocol elements. The number of trials including brachytherapy has increased over time, with over 60% of trials registered in 2010 onwards. The majority of clinical trials were Phase 2 or 3, evaluated both safety and efficacy, and were funded by academic sponsors. The most common tumor sites evaluated in brachytherapy clinical trials include prostate, cervix, liver, endometrium, and breast. There remains continued interest in clinical trials including brachytherapy focused on evaluation of novel delivery systems, treatment planning, and new indications. More brachytherapy clinical trials are needed to define the optimal clinical utilization and advance prospective research in this field.
Identifiants
pubmed: 38351013
doi: 10.1186/s13014-024-02415-8
pii: 10.1186/s13014-024-02415-8
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22Informations de copyright
© 2024. The Author(s).
Références
Chargari C, et al. Brachytherapy: an overview for clinicians. CA Cancer J Clin. 2019;69(5):386–401. https://doi.org/10.3322/caac.21578 .
doi: 10.3322/caac.21578
pubmed: 31361333
Holm HH. The history of interstitial brachytherapy of prostatic cancer. Semin Surg Oncol. 1997;13(6):431–7. https://doi.org/10.1002/(sici)1098-2388(199711/12)13:6%3c431::aid-ssu7%3e3.0.co;2-b .
doi: 10.1002/(sici)1098-2388(199711/12)13:6<431::aid-ssu7>3.0.co;2-b
pubmed: 9358590
Petereit DG, et al. Brachytherapy: where has it gone? J Clin Oncol Off J Am Soc Clin Oncol. 2015;33(9):980–2. https://doi.org/10.1200/JCO.2014.59.8128 .
doi: 10.1200/JCO.2014.59.8128
Aronowitz JN. A Century of Brachytherapy (From the Prostate’s Perspective). Springer, 2023. Accessed 16 Dec 2023. https://connect.springerpub.com/content/book/978-1-6170-5261-3/chapter/ch01
Hilaris BS. Brachytherapy in cancer of the prostate: an historical perspective. Semin Surg Oncol. 1997;13(6):399–405. https://doi.org/10.1002/(sici)1098-2388(199711/12)13:6%3c399::aid-ssu3%3e3.0.co;2-5 .
doi: 10.1002/(sici)1098-2388(199711/12)13:6<399::aid-ssu3>3.0.co;2-5
pubmed: 9358586
Zaorsky NG, et al. Evolution of brachytherapy for prostate cancer. Nat Rev Urol. 2017;14(7):415–39. https://doi.org/10.1038/nrurol.2017.76 .
doi: 10.1038/nrurol.2017.76
pubmed: 28664931
pmcid: 7542347
Chino J, et al. The ASTRO clinical practice guidelines in cervical cancer: optimizing radiation therapy for improved outcomes. Gynecol Oncol. 2020;159(3):607–10. https://doi.org/10.1016/j.ygyno.2020.09.015 .
doi: 10.1016/j.ygyno.2020.09.015
pubmed: 32972783
Chin J, et al. Brachytherapy for patients with prostate cancer: American society of clinical oncology/cancer care Ontario joint guideline update. J Clin Oncol. 2017;35(15):1737–43. https://doi.org/10.1200/JCO.2016.72.0466 .
doi: 10.1200/JCO.2016.72.0466
pubmed: 28346805
Orio PF, Nguyen PL, Buzurovic I, Cail DW, Chen Y-W. The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness. Brachytherapy. 2016;15(6):701–6. https://doi.org/10.1016/j.brachy.2016.05.001 .
doi: 10.1016/j.brachy.2016.05.001
pubmed: 27317191
Han K, Milosevic M, Fyles A, Pintilie M, Viswanathan AN. Trends in the utilization of brachytherapy in cervical cancer in the United States. Int J Radiat Oncol Biol Phys. 2013;87(1):111–9. https://doi.org/10.1016/j.ijrobp.2013.05.033 .
doi: 10.1016/j.ijrobp.2013.05.033
pubmed: 23849695
Martin JM, et al. The rise and fall of prostate brachytherapy: use of brachytherapy for the treatment of localized prostate cancer in the National Cancer Data Base. Cancer. 2014;120(14):2114–21. https://doi.org/10.1002/cncr.28697 .
doi: 10.1002/cncr.28697
pubmed: 24737481
Nabavizadeh N, et al. Results of the 2013–2015 association of residents in radiation oncology survey of chief residents in the United States. Int J Radiat Oncol Biol Phys. 2016;94(2):228–34. https://doi.org/10.1016/j.ijrobp.2015.10.014 .
doi: 10.1016/j.ijrobp.2015.10.014
pubmed: 26853332
Orio PF, Nguyen PL, Buzurovic I, Cail DW, Chen Y-W. Prostate brachytherapy case volumes by academic and nonacademic practices: implications for future residency training. Int J Radiat Oncol Biol Phys. 2016;96(3):624–8. https://doi.org/10.1016/j.ijrobp.2016.07.013 .
doi: 10.1016/j.ijrobp.2016.07.013
pubmed: 27681758
Bates JE, Thaker NG, Parekh A, Royce TJ. Geographic access to brachytherapy services in the United States. Brachytherapy. 2022;21(1):29–32. https://doi.org/10.1016/j.brachy.2021.05.004 .
doi: 10.1016/j.brachy.2021.05.004
pubmed: 34148829
Marcrom SR, et al. Brachytherapy training survey of radiation oncology residents. Int J Radiat Oncol Biol Phys. 2019;103(3):557–60. https://doi.org/10.1016/j.ijrobp.2018.10.023 .
doi: 10.1016/j.ijrobp.2018.10.023
pubmed: 30612963
Cihoric N, et al. Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database. Radiat Oncol. 2016;11(1):48. https://doi.org/10.1186/s13014-016-0624-8 .
doi: 10.1186/s13014-016-0624-8
pubmed: 27005770
pmcid: 4804566
Odei BCL, Boothe D, Lloyd S, Gaffney DK. A comprehensive analysis of brachytherapy clinical trials over the past 15 years. Brachytherapy. 2016;15(6):679–86. https://doi.org/10.1016/j.brachy.2016.06.014 .
doi: 10.1016/j.brachy.2016.06.014
pubmed: 27475486
Cunha JAM, et al. Brachytherapy future directions. Semin Radiat Oncol. 2020;30(1):94–106. https://doi.org/10.1016/j.semradonc.2019.09.001 .
doi: 10.1016/j.semradonc.2019.09.001
pubmed: 31727305
Corkum MT, et al. Is prostate brachytherapy a dying art? Trends and variation in the definitive management of prostate cancer in Ontario, Canada. Radiother Oncol. 2020;152:42–8. https://doi.org/10.1016/j.radonc.2020.07.036 .
doi: 10.1016/j.radonc.2020.07.036
pubmed: 32717361
Ghazbani A, et al. Knowledge domain and emerging trends in brachytherapy: a scientometric analysis. Precis Radiat Oncol. 2022;6(3):243–56. https://doi.org/10.1002/pro6.1171 .
doi: 10.1002/pro6.1171
Kahn JM, Campbell SR, Albert AA, Knoll MA, Shah C. #ThisIsBrachytherapy: increasing awareness of brachytherapy. Brachytherapy. 2021;20(1):232–6. https://doi.org/10.1016/j.brachy.2020.07.003 .
doi: 10.1016/j.brachy.2020.07.003
pubmed: 32811760
Taunk NK, Shah NK, Hubley E, Anamalayil S, Trotter JW, Li T. Virtual reality-based simulation improves gynecologic brachytherapy proficiency, engagement, and trainee self-confidence. Brachytherapy. 2021;20(4):695–700. https://doi.org/10.1016/j.brachy.2021.03.003 .
doi: 10.1016/j.brachy.2021.03.003
pubmed: 33824052
Williams VM, Mansoori B, Young L, Mayr NA, Halasz LM, Dyer BA. Simulation-based learning for enhanced gynecologic brachytherapy training among radiation oncology residents. Brachytherapy. 2021;20(1):128–35. https://doi.org/10.1016/j.brachy.2020.08.022 .
doi: 10.1016/j.brachy.2020.08.022
pubmed: 33158776
Williams VM, et al. The case for brachytherapy: why it deserves a renaissance. Adv Radiat Oncol. 2021;6(2):100605. https://doi.org/10.1016/j.adro.2020.10.018 .
doi: 10.1016/j.adro.2020.10.018
pubmed: 33723523
Colson-Fearon D, Han K, Roumeliotis MB, Viswanathan AN. Updated Trends in Brachytherapy Utilization and Disparities in the United States from 2004 to 2020. Int J Radiat Oncol Biol Phys. 2023. https://doi.org/10.1016/j.ijrobp.2023.11.036 .
doi: 10.1016/j.ijrobp.2023.11.036
pubmed: 38040060
pmcid: 10842819
Han K, Colson-Fearon D, Liu ZA, Viswanathan AN. Updated trends in the utilization of brachytherapy in cervical cancer in the united states: a surveillance, epidemiology, and end-results study. Int J Radiat Oncol Biol Phys. 2023. https://doi.org/10.1016/j.ijrobp.2023.11.007 .
doi: 10.1016/j.ijrobp.2023.11.007
pubmed: 38147912
Chargari C, et al. Radiotherapy of cervical cancer. Cancer Radiother J Soc Francaise Radiother Oncol. 2022;26(1–2):298–308. https://doi.org/10.1016/j.canrad.2021.11.009 .
doi: 10.1016/j.canrad.2021.11.009
Viswanathan AN, Thomadsen B, American Brachytherapy Society Cervical Cancer Recommendations Committee, and American Brachytherapy Society. American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part I: general principles. Brachytherapy. 2012;11(1):33–46. https://doi.org/10.1016/j.brachy.2011.07.003 .
doi: 10.1016/j.brachy.2011.07.003
pubmed: 22265436
Harkenrider MM, et al. Radiation therapy for endometrial cancer: an American society for radiation oncology clinical practice guideline. Pract Radiat Oncol. 2023;13(1):41–65. https://doi.org/10.1016/j.prro.2022.09.002 .
doi: 10.1016/j.prro.2022.09.002
pubmed: 36280107
Kamrava M, et al. American Brachytherapy Society recurrent carcinoma of the endometrium task force patterns of care and review of the literature. Brachytherapy. 2017;16(6):1129–43. https://doi.org/10.1016/j.brachy.2017.07.012 .
doi: 10.1016/j.brachy.2017.07.012
pubmed: 28888417
Cancer Genome Atlas Research Network et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67–73. https://doi.org/10.1038/nature12113 .
RAINBO Research Consortium. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 2022;33(1):109–117. https://doi.org/10.1136/ijgc-2022-004039 .
Horeweg N, et al. Molecular classification predicts response to radiotherapy in the randomized PORTEC-1 and PORTEC-2 trials for early-stage endometrioid endometrial cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2023;41(27):4369–80. https://doi.org/10.1200/JCO.23.00062 .
doi: 10.1200/JCO.23.00062
Shah C, et al. The American Brachytherapy Society consensus statement for accelerated partial-breast irradiation. Brachytherapy. 2018;17(1):154–70. https://doi.org/10.1016/j.brachy.2017.09.004 .
doi: 10.1016/j.brachy.2017.09.004
pubmed: 29074088
Hepel JT, et al. American Brachytherapy Society consensus report for accelerated partial breast irradiation using interstitial multicatheter brachytherapy. Brachytherapy. 2017;16(5):919–28. https://doi.org/10.1016/j.brachy.2017.05.012 .
doi: 10.1016/j.brachy.2017.05.012
pubmed: 28676428
Cozzi S, et al. The role of interstitial brachytherapy for breast cancer treatment: an overview of indications, applications, and technical notes. Cancers. 2022;14(10):2564. https://doi.org/10.3390/cancers14102564 .
doi: 10.3390/cancers14102564
pubmed: 35626168
pmcid: 9139312
Major T, et al. Recommendations from GEC ESTRO Breast Cancer Working Group (II): target definition and target delineation for accelerated or boost partial breast irradiation using multicatheter interstitial brachytherapy after breast conserving open cavity surgery. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2016;118(1):199–204. https://doi.org/10.1016/j.radonc.2015.12.006 .
doi: 10.1016/j.radonc.2015.12.006
Schäfer R, et al. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial. Lancet Oncol. 2018;19(6):834–44. https://doi.org/10.1016/S1470-2045(18)30195-5 .
doi: 10.1016/S1470-2045(18)30195-5
pubmed: 29695348
Hannoun-Levi J-M, et al. Accelerated partial breast irradiation with interstitial brachytherapy as second conservative treatment for ipsilateral breast tumour recurrence: multicentric study of the GEC-ESTRO Breast Cancer Working Group. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2013;108(2):226–31. https://doi.org/10.1016/j.radonc.2013.03.026 .
doi: 10.1016/j.radonc.2013.03.026
Strnad V, et al. Accelerated partial breast irradiation using sole interstitial multicatheter brachytherapy compared with whole-breast irradiation with boost for early breast cancer: 10-year results of a GEC-ESTRO randomised, phase 3, non-inferiority trial. Lancet Oncol. 2023;24(3):262–72. https://doi.org/10.1016/S1470-2045(23)00018-9 .
doi: 10.1016/S1470-2045(23)00018-9
pubmed: 36738756
Smith GD, et al. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis. Int J Radiat Oncol Biol Phys. 2015;91(3):505–16. https://doi.org/10.1016/j.ijrobp.2014.11.018 .
doi: 10.1016/j.ijrobp.2014.11.018
pubmed: 25596107
Morris WJ, et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2017;98(2):275–85. https://doi.org/10.1016/j.ijrobp.2016.11.026 .
doi: 10.1016/j.ijrobp.2016.11.026
pubmed: 28262473
Nguyen PL, et al. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol. 2012;188(4):1151–6. https://doi.org/10.1016/j.juro.2012.06.010 .
doi: 10.1016/j.juro.2012.06.010
pubmed: 22901567
pmcid: 3744091
Peters M, et al. Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2014;112(1):77–82. https://doi.org/10.1016/j.radonc.2014.06.013 .
doi: 10.1016/j.radonc.2014.06.013
Moideen N, Falkson CB, Hopman W, Mahmud A. Brachytherapy in the management of esophageal cancer: a single institution experience. Int J Radiat Oncol Biol Phys. 2018;102(3):e36. https://doi.org/10.1016/j.ijrobp.2018.07.532 .
doi: 10.1016/j.ijrobp.2018.07.532
Steyerberg EW, Homs MYV, Stokvis A, Essink-Bot M-L, Siersema PD, SIREC Study Group. Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointest Endosc. 2005;62(3):333–40. https://doi.org/10.1016/s0016-5107(05)01587-7 .
doi: 10.1016/s0016-5107(05)01587-7
pubmed: 16111947
Hong K, et al. ACR–ABS–ACNM–ASTRO–SIR–SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies. Brachytherapy. 2021;20(3):497–511. https://doi.org/10.1016/j.brachy.2021.01.006 .
doi: 10.1016/j.brachy.2021.01.006
pubmed: 33824051
Apisarnthanarax S, et al. External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline. Pract Radiat Oncol. 2022;12(1):28–51. https://doi.org/10.1016/j.prro.2021.09.004 .
doi: 10.1016/j.prro.2021.09.004
pubmed: 34688956
Wust P, et al. Radiotherapeutic treatment options for oligotopic malignant liver lesions. Radiat Oncol Lond Engl. 2021;16(1):51. https://doi.org/10.1186/s13014-021-01779-5 .
doi: 10.1186/s13014-021-01779-5
Walter F, et al. Interstitial high-dose-rate brachytherapy of liver metastases in oligometastatic patients. Cancers. 2021;13(24):6250. https://doi.org/10.3390/cancers13246250 .
doi: 10.3390/cancers13246250
pubmed: 34944869
pmcid: 8699459
Nag S, DeHaan M, Scruggs G, Mayr N, Martin EW. Long-term follow-up of patients of intrahepatic malignancies treated with iodine-125 brachytherapy. Int J Radiat Oncol Biol Phys. 2006;64(3):736–44. https://doi.org/10.1016/j.ijrobp.2005.08.029 .
doi: 10.1016/j.ijrobp.2005.08.029
pubmed: 16274935
Zhou L, Yang H, Xie L, Sun J, Qian J, Zhu L. Comparison of image-guided iodine-125 seed interstitial brachytherapy and local chemotherapy perfusion in treatment of advanced pancreatic cancer. J Investig Surg Off J Acad Surg Res. 2022;35(1):1–6. https://doi.org/10.1080/08941939.2020.1805057 .
doi: 10.1080/08941939.2020.1805057
Wang Y, et al. A novel tracheobronchial stent loaded with 125I seeds in patients with malignant airway obstruction compared to a conventional stent: a prospective randomized controlled study. EBioMedicine. 2018;33:269–75. https://doi.org/10.1016/j.ebiom.2018.06.006 .
doi: 10.1016/j.ebiom.2018.06.006
pubmed: 29909977
pmcid: 6085500
Gerard J-P, et al. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8(4):356–67. https://doi.org/10.1016/S2468-1253(22)00392-2 .
doi: 10.1016/S2468-1253(22)00392-2
pubmed: 36801007